These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Ongoing||2006-002372-18||Pilot Study of the Intravesical Administration of EOquin Immediately Following Transurethral Resection in Patients with Superficial Bladder Cancer.||not-yet-due|
|Reported results||2008-005843-40||A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma||2014-10-27||due-trials|
|Reported results||2009-015404-26||A Multicenter, Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial of Single-Dose Intravesical EOquinâ as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing ...||2012-01-03||due-trials|
|Reported results||2011-003517-42||A Phase 3 International, Multicenter, Double-Blind, Placebo-Controlled, Randomized Trial Evaluating the Efficacy and Safety of Multiple Instillations of Intravesical Apaziquone vs. Placebo in Patients...||2013-02-21||due-trials|
|Reported results||2011-004916-51||A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (ibritumomab tiuxetan) versus Observation in Patients at Least 60 Years of Age with Newly Diagnosed Diffuse Large B-cell Ly...||2014-10-30||due-trials|
|Reported results||2013-003094-10||Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim use for the Management of Neutropenia in Patients with Breast Cancer who are Candidates for Adjuvant and Neoadjuvant Chemotherapy w...||2015-02-06||due-trials|
|Reported results||2016-003469-24||Randomized, OpEn-Label, Active-ContrOl Trial of SPI-2012 (Eflapegrastim) Versus Pegfilgrastim in the Management of Chemotherapy-Induced Neutropenia in Early-Stage BReast Cancer Patients Receiving Doce...||2019-04-16||due-trials|
|Listed as ongoing, but also has a completion date||2018-001868-36||A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)||2023-04-03||bad-data|
|Ongoing||2020-005213-40||An Open-Label Extension Study to Allow Continued Dosing and/or Follow-up of Patients who have had Previous Exposure to Poziotinib Studio di estensione in aperto per consentire la prosecuzione del t...||not-yet-due|